1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 3, 2001
The Medicines Company
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31191 04-3324394
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
One Cambridge Center
Cambridge, MA 02142
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 225-9099
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
2
ITEM 5. OTHER EVENTS.
On October 3, 2001, The Medicines Company issued an announcement in
connection with its revised revenue guidance for 2001 and 2002.
The full text of the press release issued in connection with the
announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release dated October 3, 2001
announcing revised revenue guidance
by the Registrant for 2001 and 2002
-2-
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 4, 2001 THE MEDICINES COMPANY
By: /s/ Peyton J. Marshall
-----------------------------------
Name: Peyton J. Marshall
Title: Senior Vice President and Chief
Financial Officer
-3-
4
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated October 3, 2001
announcing revised revenue guidance
by the Registrant for 2001 and 2002